- Home
- PETZ vs AYTU Comparison
PETZ vs AYTU Comparison
Compare PETZ & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETZ
- AYTU
- Stock Information
- Founded
- PETZ 2002
- AYTU N/A
- Country
- PETZ China
- AYTU United States
- Employees
- PETZ N/A
- AYTU N/A
- Industry
- PETZ Steel/Iron Ore
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- PETZ Industrials
- AYTU Health Care
- Exchange
- PETZ Nasdaq
- AYTU Nasdaq
- Market Cap
- PETZ 9.3M
- AYTU 9.6M
- IPO Year
- PETZ 2017
- AYTU N/A
- Fundamental
- Price
- PETZ N/A
- AYTU $2.39
- Analyst Decision
- PETZ
- AYTU Strong Buy
- Analyst Count
- PETZ 0
- AYTU 2
- Target Price
- PETZ N/A
- AYTU $10.00
- AVG Volume (30 Days)
- PETZ 6.7K
- AYTU 669.1K
- Earning Date
- PETZ 04-28-2025
- AYTU 05-14-2025
- Dividend Yield
- PETZ N/A
- AYTU N/A
- EPS Growth
- PETZ N/A
- AYTU N/A
- EPS
- PETZ 0.26
- AYTU N/A
- Revenue
- PETZ $563,726.00
- AYTU $81,659,000.00
- Revenue This Year
- PETZ N/A
- AYTU N/A
- Revenue Next Year
- PETZ N/A
- AYTU $8.68
- P/E Ratio
- PETZ $4.99
- AYTU $13.06
- Revenue Growth
- PETZ 74664.72
- AYTU 0.41
- 52 Week Low
- PETZ $0.65
- AYTU $0.95
- 52 Week High
- PETZ $1.74
- AYTU $2.96
- Technical
- Relative Strength Index (RSI)
- PETZ 51.06
- AYTU 70.58
- Support Level
- PETZ $0.95
- AYTU $2.04
- Resistance Level
- PETZ $1.08
- AYTU $2.40
- Average True Range (ATR)
- PETZ 0.08
- AYTU 0.14
- MACD
- PETZ -0.00
- AYTU 0.02
- Stochastic Oscillator
- PETZ 51.44
- AYTU 87.27
About PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling pet food and restaurant operations. The company has two operating segments, which include Petfood sales and the Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.